08.08.2012 - Pfizer, Johnson & Johnson and Elan will end the development of bapineuzumab. The antibody was thought to become a treatment for Alzheimer's disease with hundreds of millions in sale.
The decision came after the antibody targeting amyloid beta did not meet the co-primary endpoints of change in cognitive and functional performance in a phase III study in patients lacking a mutation in the apolipoprotein E epsilon. The trial was led by J&J's research affiliate Janssen Cilag. Some experts said the result came as no surprise as the window of success was very small. Nevertheless, Bapineuzumab is one of the most advanced antibodies targeting amyloid beta. For Elan's future, the study failure could have a large effect. The company was responsible to pay for 49,9% of the trial costs. That leads to a US-$117.3m non-cash impairment charge in the third quarter of 2012. Elan shares fell more than 12%. Analysts speculated that the the success of bapineuzumab could influence a potential sale of the company, noting that Elan's partner Biogen Idec could step in at the right price.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.